Company intelligence / Profile preview

Brennen Medical

Saint Paul, Minnesota, United States

Ownership: Private
Development stage: Other

Overview

Brennen Medical was a medical device company specializing in tissue repair technologies, including oat beta glucan and porcine xenograft products for wound, burn, and surgical care. Its key assets were acquired by Genzyme Corporation in 2009 and Molnlycke Health Care in 2012, leading to its inactivation.

Therapeutic areas: OtherDermatologyGastroenterology
Industry: Therapeutic Medical Devices

Partnerships

Genzyme Corporation (product sale of GlucaTex® and GlucaMesh® hernia repair products, 2009)Molnlycke Health Care (acquisition of burn and wound care business assets including porcine xenograft, beta-glucan products, graft meshers, 2012)

Beyond the preview

Go deeper on Brennen Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brennen Medical.

Explore the full profile